Shares of BioCryst Pharmaceuticals (BCRX) shoot up 11% premarket after the firm announces...

|About: BioCryst Pharmaceuticals,... (BCRX)|By:, SA News Editor

Shares of BioCryst Pharmaceuticals (BCRX) shoot up 11% premarket after the firm announces positive top-line results for a Phase 2 study of its gout treatment that met its main goal.